About Flashpoint Therapeutics
Flashpoint Therapeutics is a company based in Palo Alto (United States) founded in 2022 by Adam Margolin, Chad Mirkin, and Michelle Teplensky. Flashpoint Therapeutics has raised $10 million across 1 funding round from investors including Beta Lab. Flashpoint Therapeutics operates in a competitive market with competitors including Curapath, Biocydex, Magle Group, Vim Meditech and DNA Nanobots, among others.
- Headquarter Palo Alto, United States
- Founders Adam Margolin, Chad Mirkin, Michelle Teplensky
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Seed
Oct 25, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Flashpoint Therapeutics
Flashpoint Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Flashpoint Therapeutics
Flashpoint Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Beta Lab.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Beta Lab is recognized as a leading investment firm focused on global business growth.
|
Locked | Locked | Locked |
Investor details for Flashpoint Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Flashpoint Therapeutics
Investment portfolio details for Flashpoint Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Flashpoint Therapeutics
Detailed financials for Flashpoint Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Flashpoint Therapeutics Comparisons
Peer comparison for Flashpoint Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Flashpoint Therapeutics
Flashpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Curapath, Biocydex, Magle Group, Vim Meditech and DNA Nanobots, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drug delivery systems for therapeutic purposes
|
|
| Locked | Locked | Locked |
Preclinical drug discovery, formulation and drug delivery R&D services
|
|
| Locked | Locked | Locked |
Develops medical technologies for pharmaceuticals, therapeutics, and biopolymers.
|
|
| Locked | Locked | Locked |
Specializes in developing and manufacturing innovative parenteral drug delivery systems and sterile injectables.
|
|
| Locked | Locked | Locked |
Targeted chemotherapy, vaccines, and gene therapy are delivered via nanotechnology.
|
Detailed competitors of Flashpoint Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Flashpoint Therapeutics
Complete news archive for Flashpoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Flashpoint Therapeutics
Flashpoint Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Flashpoint Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Adam Margolin is the current CEO of Flashpoint Therapeutics. They have also founded this company.
Flashpoint Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date.
Flashpoint Therapeutics is a company that is developing nanotherapeutic candidates to deliver precise RNA, DNA, and peptide payloads to specific cells at the right time. They are pioneering nanotechnology-enabled medicines.
Flashpoint Therapeutics's top competitors include Curapath, DNA Nanobots and Biocydex.
Flashpoint Therapeutics has 1 investor. Key investors include Beta Lab.